Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akeso
With
Summit Therapeutics
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven diagnosis of colorectal adenocarcinoma
Part1: Subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
Part2: Subjects who have previously received systemic therapy including fluorouracil, oxaliplatin, irinotecan, bevacizumab or anti-EGFR antibodies or could not tolerate or have contraindications to standard treatment
Eastern Cooperative Oncology Group performance status of 0 or 1
Measurable disease as defined by RECIST v1.1
Adequate hematologic and organ function
You may not be if
Known MSI-H(Microsatellite-Instability-High) or dMMR(Mismatch Repair-Deficient)
Prior treatment with immunotherapy, including immune checkpoint inhibitors , immune checkpoint agonists, immune cell therapy and any treatment targeting tumor immune pathway
History of autoimmune disease
Prior allogeneic stem cell or solid organ transplantation
Positive test for human immunodeficiency virus,Active hepatitis B or hepatitis C
Receipt of a live, attenuated vaccine within 30 days prior to randomization, during treatment
